
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is positioned favorably because its lead asset, IGC-AD1, has already delivered a clinically and statistically significant reduction in agitation versus placebo in March 2024, while also showing preclinical potential against plaques and tangles in Alzheimer’s cell lines. The Phase 2 CALMA trial has reached its original enrollment target of 146 patients in August, is within 6 randomizations of closure, and is expected to deliver topline data in Q4 2026, creating a clear near-term catalyst path alongside the planned AI beta program. With 5 Alzheimer’s candidates, 2 later-stage assets, and a market opportunity framed as billion-dollar potential in a disease with no known cure, the fundamentals support a high-risk, high-reward bullish outlook.
Bears say
IGC Pharma is a highly speculative biotech name whose value depends on unproven cannabinoid-based formulations, including investigational assets for Alzheimer’s disease, that have only shown potential in cell lines rather than validated clinical outcomes. The thesis is weakened by substantial balance sheet and liquidity risk, along with the possibility that product candidates may fail on safety, efficacy, or regulatory approval, which would prevent commercialization and reimbursement. Even if development progresses, the company still faces intense competition, shifting macroeconomic conditions, weak biotech investor sentiment, and changing consumer or government healthcare priorities, all of which could pressure fundamental performance.
This aggregate rating is based on analysts' research of IGC Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About IGC Pharma Inc (IGC) Forecast
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares